Asthma Clinical Trials

What Is State Of the Art In Asthma?

Asthma Clinical Trials
Joos Mind Collection/Stone/Getty Images

 Before your doctor can prescribe a medication for you, asthma clinical trials must be performed. Trials initially test safety and tolerability of the investigational product in healthy subjects, and then move on to testing effectiveness in patients with asthma.

Participating in a clinical trial has many benefits including access to great asthma doctors as well as potentially new drugs not yet released for use.

It also has some downsides like lengthy and more frequent visits than you may be used to. A number of my patients have participated in clinical trials and really enjoyed the experience.

There are a number of asthma clinical trials in progress that may lead to a new treatment for your asthma in the next few years. You can find out more about asthma clinical trials by going to Some of the trials include:

  • CNTO 3157. Currently, Xolair is the only monoclonal antibody available for the treatment of asthma. Despite adhering to their treatment regimen, there is still a group of severe asthmatics who remain symptomatic despite good treatment.

    CNTO 3157 is an investigational product that will eventually target these patients if it continues to proceed through the drug development process. This monoclonal antibody targets development of specific cytokines in the pathophysiology of asthma and is currently in phase 1 clinical trials.

  • Pioglitazone. The purpose of this clinical trial is to look at asthma flares in overweight asthmatics. Researchers believe that overweight and obesity leads to elevated levels of leptin and lower-than-normal levels of adiponectin in the blood. Population-based studies have shown potential relationships between these hormones and asthma.

    Pioglitazone is a currently marketed as a treatment for diabetes and may decrease leptin levels while increasing adiponectin. The hope is that treatment will help asthma patients obtain better control.

  • ALK HDM. The purpose of this clinical trial is to see if a treatment with house dust mite allergen immunotherapy tablet reduces asthma exacerbations in patients known to be sensitive to dust mites.

  • Vitamin D. Vitamin D was recently identified as a possible treatment option when low vitamin D levels were associated with increased systemic steroid use and lab data demonstrating why low vitamin D levels may make a patient less responsive to treatment with steroids. The clinical trial will supplement vitamin D deficient patients either orally with a daily supplementation or with a single injection. The researchers want to know if one treatment decreases asthma exacerbations compared to the other.

  • Allergen extracts. Immunotherapy has been studied in the treatment of asthma for older children and adults, but it has not been studied extensively in the 18 month to 3 year age group. This asthma clinical trial is examining if tailored treatment with immunotherapy can decrease asthma medication use in young children with multiple episodes of wheezing and at high risk for developing asthma.

  • Citalopram. Asthma, like many chronic diseases, increase risk of depression and other psychological symptoms. However, there is little objective evidence that treating these symptoms modifies a patient's asthma control. Investigators hope to determine if treating depressive symptoms has any effect on outcomes such as depression symptoms, medication use, and asthma control score.

  • NIOX MINO. This asthma clinical trial is looking at standard therapy compared to tailored therapy based on home measurement of exhaled nitric oxide levels. Exhaled nitric oxide levels can be seen as a proxy for airway hyperresponsiveness and severity of airway inflammation. Patients asthma action plan will be based on exhaled nitric oxide levels and outcomes will be based on self-reported symptom scores.

  • Telehealth and asthma. In this study, investigators want to see if a telehealth program can improve asthma outcomes. The study is looking at electronic online action plan supplemented by weekly text messages decreases asthma exacerbations, improves control, and quality of life.

Sources 1. Accessed October 24, 2015.

Continue Reading